There is currently only one drug approved for the treatment of Myelofibrosis, with other off-label conventional therapies also used, but none of these drugs are curative. The only potentially curative intervention is allogeneic stem cell transplant (allo-SCT), which is available to a very small percentage of eligible patients because of the high risk of morbidity and mortality. However, new treatments are in advanced phases of clinical testing. Capitalizing on our unique expertise in patient chart-based research we have designed this syndicated study based on real world data to monitor the impact of the new treatments for Myelofibrosis management.


Fill in the form below to access an overview of our Biosimilar syndicated studies including:

  • Objectives 
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves